Phase 2 N=68 Repeated Partial Sleep Deprivation to Augment SSRI Response in Depression
Depression
Primary: Hamilton Rating Scale for Depression-17 Item Minus Sleep Items — 6.1; 8.1; 6.3 units on a scale — p=.202
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=66 Effects of Tai Chi on Frailty in Elderly Adults
Frailty
Primary: Frailty Index — 7; 5; 16; 21 participants — p=0.15
Phase 3 N=25 Ultrasound Scores as Indication of Response to Subcutaneous Abatacept in Subjects With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: 12 Month Change in 7-Joint Ultrasound (US) Inflammatory Score — 11.4 units on a scale — p=<0.01
Phase 1 N=5 Topical Bethanechol for Improvement of Esophageal Dysmotility
Esophageal Dysmotility
Primary: Distal Contractile Integral — 178.3; 272.3; 261.8 mmHg*s*cm
Phase 1 N=46 Pharmacokinetics, Pharmacodynamics, and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Primary: Cmax: Maximum Observed Plasma Concentration for Alogliptin — 57.82; 101.38; 44.24; 96.74 ng/mL
Phase 4 N=20 Treatment of Lower Extremity Spider Veins With Excel V
Telangiectasis · Spider Veins
Primary: Mean Improvement of Lower Extremity Spider Veins Based on Blinded Photo Assessments — 2.5 points on Improvement scale
Phase 1 N=52 Study To Investigate The Relative Bioavailability of OZ439 Formulations In Healthy Volunteers
Healthy Volunteers
Primary: OZ439 Cmax — 1910; 827; 1930; 1440 ng/ml
Phase 4 N=60 One Hour Preoperative Gatifloxacin
Ophthalmic Surgery
Primary: Number of Participant With Positive Culture — 17 participants
N/A N=150 Bleeding Patterns and Complications After Postpartum IUD Placement: a Pilot Study
Postpartum Period
Primary: Bleeding Patterns — 15; 18; 13; 7 days
Phase 2 N=363 Safety and Efficacy Study of Dexamethasone Versus Ranibizumab in Patients With Diabetic Macular Edema
Macular Edema
Primary: Average Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye — 60.2; 60.4; 4.34; 7.60 Letters
Phase 2 N=29 Study of Oxaliplatin Plus Bevacizumab in Germ Cell Tumor Patients
Neoplasms, Germ Cell and Embryonal
Primary: Twelve Month Disease-free Survival Rate — 3.5 percentage of participants
N/A N=25 An Investigation of Ostomy Devices
Ileostomy
Primary: Degree of Leakage — 4.2; 4.3; 4.4; 4.3 units on a scale
N/A N=16,789 Chronic Migraine Epidemiology and Outcomes Study
Migraine Disorders
Primary: Percentage of Participants With Episodic Migraine (EM) or Chronic Migraine (CM) — 91.2; 8.8 percentage of participants
Phase 2 N=60 Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma
Esophageal Neoplasms · Stomach Neoplasms · Neoplasm Metastasis
Primary: Median Progression-Free Survival (PFS) — 6.97 survival time in months
Phase 3 N=124 NIV Strategies for RDS in Preterm Infants. NIV (Non Invasive Ventilation), RDS (Respiratory Distress Syndrome)
RDS of Prematurity
Primary: Duration of NIV Support — 89; 87 HOURS — p=< 0.05